The tyrosine kinase inhibitor axitinib targets T315I gatekeeper-mutant Philadelphia chromosome-positive leukemias in vitro and in vivo

被引：0
|
作者：
Pemovska, Tea [1 ]
Kontro, Mika [2 ,3 ]
Repasky, Gretchen A. [1 ]
Porkka, Kimmo [2 ,3 ]
Wennerberg, Krister [1 ]
机构：
[1] FIMM, Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, Hematol Res Unit Helsinki, Helsinki, Finland
[3] Univ Helsinki, Helsinki, Finland
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-4763
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4763
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
    Chan, Wayne W.
    Wise, Scott C.
    Kaufman, Michael D.
    Ahn, Yu Mi
    Ensinger, Carol L.
    Haack, Torsten
    Hood, Molly M.
    Jones, Jennifer
    Lord, John W.
    Lu, Wei Ping
    Miller, David
    Patt, William C.
    Smith, Bryan D.
    Petillo, Peter A.
    Rutkoski, Thomas J.
    Telikepalli, Hanumaiah
    Vogeti, Lakshminarayana
    Yao, Tony
    Chun, Lawrence
    Clark, Robin
    Evangelista, Peter
    Gavrilescu, L. Cristina
    Lazarides, Katherine
    Zaleskas, Virginia M.
    Stewart, Lance J.
    Van Etten, Richard A.
    Flynn, Daniel L.
    CANCER CELL, 2011, 19 (04) : 556 - 568
  • [32] A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph+) Leukemias Including Patients with T315I Mutation
    Cortes, Jorge E.
    Talpaz, Moshe
    Kantarjian, Hagop M.
    Smith, Hedy
    Bixby, Dale
    Rafferty, Usha
    Berger, Mark S.
    Wise, Scott C.
    Rutkoski, Tom J.
    Smith, Bryan
    Van Etten, Richard A.
    BLOOD, 2011, 118 (21) : 276 - 276
  • [33] A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
    Seymour, J. F.
    Kim, D. W.
    Rubin, E.
    Haregewoin, A.
    Clark, J.
    Watson, P.
    Hughes, T.
    Dufva, I.
    Jimenez, J. L.
    Mahon, F-X
    Rousselot, P.
    Cortes, J.
    Martinelli, G.
    Papayannidis, Cristina
    Nagler, A.
    Giles, F. J.
    BLOOD CANCER JOURNAL, 2014, 4 : e238 - e238
  • [34] A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
    J F Seymour
    D W Kim
    E Rubin
    A Haregewoin
    J Clark
    P Watson
    T Hughes
    I Dufva
    J L Jimenez
    F-X Mahon
    P Rousselot
    J Cortes
    G Martinelli
    C Papayannidis
    A Nagler
    F J Giles
    Blood Cancer Journal, 2014, 4 : e238 - e238
  • [35] Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia
    Assi, Rita
    Kantarjian, Hagop
    Short, Nicholas J.
    Daver, Naval
    Takahashi, Koichi
    Garcia-Manero, Guillermo
    DiNardo, Courtney
    Burger, Jan
    Cortes, Jorge
    Jain, Nitin
    Wierda, William
    Chamoun, Salim
    Konopleva, Marina
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (12): : 897 - 901
  • [36] Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia
    Assi, Rita
    Kantarjian, Hagop
    Short, Nicholas J.
    Daver, Naval
    Takahashi, Koichi
    Garcia-Manero, Guillermo
    DiNardo, Courtney
    Khouri, Rita
    Burger, Jan
    Jain, Nitin
    Wierda, William
    Chamoun, Salim
    Konopleva, Marina
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S265 - S265
  • [37] Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia
    Assi, Rita
    Kantarjian, Hagop M.
    Short, Nicholas J.
    Daver, Naval
    Takahashi, Koichi
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    Khouri, Maria
    Burger, Jan A.
    Cortes, Jorge E.
    Jain, Nitin
    Wierda, William G.
    Chamoun, Salim
    Konopleva, Marina
    Jabbour, Elias J.
    BLOOD, 2017, 130
  • [38] Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation
    Chen, Huan
    Xu, Lan -ping
    Zhang, Xiao-hui
    Wang, Yu
    Chen, Yu-hong
    Yan, Chen-hua
    Cheng, Yi-fei
    Han, Wei
    Chen, Yao
    Qin, Ya-zhen
    Liu, Yanrong
    Chang, Ying-jun
    Liu, Kai-yan
    Huang, Xiao-jun
    LEUKEMIA RESEARCH, 2022, 121
  • [39] Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph plus CML-CP) with and without the T315I Mutation
    Combes, Francois Pierre
    Li, Ying Fei
    Sy, Sherwin K. B.
    Lorenzo, Sebastien
    Dasgupta, Kohinoor
    Kapoor, Shruti
    Hoch, Matthias
    Ho, Yu-Yun
    BLOOD, 2022, 140 : 6791 - 6792
  • [40] What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?
    Haddad, Fadi G.
    Short, Nicholas J.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2022, (01) : 213 - 217
12345